"Asparaginase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A hydrolase enzyme that converts L-asparagine and water to L-aspartate and NH3. EC 3.5.1.1.
| Descriptor ID |
D001215
|
| MeSH Number(s) |
D08.811.277.087.116
|
| Concept/Terms |
Asparaginase- Asparaginase
- Asparagine Deaminase
- Deaminase, Asparagine
- Colaspase
- Asparaginase II
|
Below are MeSH descriptors whose meaning is more general than "Asparaginase".
Below are MeSH descriptors whose meaning is more specific than "Asparaginase".
This graph shows the total number of publications written about "Asparaginase" by people in this website by year, and whether "Asparaginase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 2 | 3 |
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 1 | 3 |
| 2018 | 0 | 3 | 3 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 1 | 2 |
| 2022 | 1 | 1 | 2 |
| 2023 | 0 | 2 | 2 |
| 2025 | 2 | 0 | 2 |
| 2026 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Asparaginase" by people in Profiles.
-
Clinical and demographic factors contributing to asparaginase-associated toxicities in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2022 12; 63(12):2948-2954.
-
Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2018 03; 65(3).
-
A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL08P1. J Pediatr Hematol Oncol. 2016 08; 38(6):409-17.
-
Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia. Pediatr Blood Cancer. 2016 Feb; 63(2):228-33.
-
Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2015 Feb; 90(2):120-4.
-
Augmented Berlin-Frankfurt-M?nster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer. 2014 Dec 01; 120(23):3660-8.
-
Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial. Pediatr Blood Cancer. 2014 Jul; 61(7):1232-8.
-
Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma. Pediatr Blood Cancer. 2014 May; 61(5):810-4.
-
Red blood cell-encapsulated L-asparaginase: potential therapy of patients with asparagine synthetase deficient acute myeloid leukemia. Protein Pept Lett. 2013 Apr; 20(4):392-402.
-
Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):54-9.